



Fungal Pathogens: Resistance and Novel Therapeutics

Guest Editors:

Dr. Ryan Kean

Department of Biological and
Biomedical Sciences, School of
Health and Life Sciences,
Glasgow Caledonian University,
Glasgow, UK

Dr. Leighann Sherry

School of Life Sciences, College
of Medical, Veterinary and Life
Sciences, University of Glasgow,
Glasgow, UK

Deadline for manuscript
submissions:

closed (30 June 2020)

Message from the Guest Editors

Dear Colleagues,

Fungal infections play a surprising yet unrecognised health burden on the global population, with diseases ranging from superficial infections to life-threatening bloodstream infections. Most pathogenic fungi are regarded as opportunistic, capable of causing debilitating disease in immunocompromised individuals and are commonly associated with unacceptably high mortality rates, accounting for ~1.6 million deaths each year. In a climate where antimicrobial resistance continues to increase and the rate of new drug discovery slows, coupled with the unprecedented emergence of new fungal pathogens such as *Candida auris*, it is of paramount interest to fully understand the underlying mechanisms of resistance and use these findings to translate and identify alternative strategies for the management of fungal infections.

This special issue welcomes original research and review articles and aims to collate the most recent findings on antifungal resistance and highlight potential novel therapeutics for the clinical management of these infections.

Dr. Ryan Kean
Dr. Leighann Sherry
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)